whitepaper
Guide: Eight tips for ensuring a successful ELISA
Learn quick technical tips to optimise your ELISA workflow, including how to: select the right ELISA kit, avoid contamination and normalise data.
List view / Grid view
Targets
news
Synthetic antibody treats congenital myasthenia in mice
Researchers have designed an antibody that attaches to MuSK, which prevented early lethality of mice with congenital myasthenia.
news
Structural changes in SARS-CoV-2 Alpha and Beta variants revealed
A study has uncovered previously unknown properties of the Spike protein from the SARS-CoV-2 Alpha and Beta variants.
news
Study of liver cancer reveals MAGEA3 gene as new drug target
A study has shown that blocking the gene expression of MAGEA3 in liver cancer cells prevents the tumour from proliferating.
news
New class of compounds found to block coronavirus reproduction
In cell cultures, a compound named STM2457 was shown to interfere with coronavirus replication, making it a potential treatment for SARS-CoV-2.
video
Video: Sino Biological: the global leader in recombinant technology
Sino Biological is an international reagent supplier and service provider. The company specialises in recombinant protein production and antibody development.
whitepaper
Brochure: Viral research solutions
Solutions to help you understand viral diseases and translate your research findings into better treatments and vaccines.
whitepaper
Application note: Pushing the boundaries in pharmaceutical hit discovery with the novel waveRAPID® kinetic assay
We demonstrate the power of waveRAPID in streamlining the kinetic characterisation of large numbers of drug hit compounds, with results comparable to traditional surface plasmon resonance (SPR) and high reproducibility.
whitepaper
Application note: Improving and simplifying the design of knock-in experiments using the TrueDesign Genome Editor
Genome editing technologies have given investigators the power to unlock a variety of new applications and experimental approaches. While gene knockouts have been achievable for several years, successful gene knock-ins have remained elusive due to the low efficiency of homology-directed repair (HDR).
article
Under the microscope: Exploring phage display technologies for drug discovery and early development
With over 20 years’ of expertise in phage display, IRBM applies its extensive peptide and antibody libraries to discover lead therapeutic candidates. Dr Licia Tomei, Director of Display Technologies, IRBM, discusses the company’s phage display capabilities and how they accelerate the drug discovery process.
news
Intestinal bacteria found to produce SARS-CoV-2-inhibiting compounds
Researchers have screened bacteria in the gut, finding that Bifidobacteria have inhibitory activity against SARS-CoV-2.
article
How to mix the best anti-SARS-CoV-2 cocktail
Neutralisation resistance generated by Spike (S) protein mutations in Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) poses a challenge to antibody therapies for COVID-19. Antibody cocktails targeting the S protein receptor binding domain (RBD) are one way to avoid viral neutralisation escape, however only certain antibody combinations are currently effective.…
whitepaper
Catalogue: Resources for COVID-19 and influenza vaccine development
A panel of SARS-CoV-2 reagents (e.g. antigens, antibodies, and kits) and influenza antigens have been developed to support the development of vaccines.
news
Nanodecoy therapy neutralises SARS-CoV-2 in macaques
Lung spheroid cells can act as nanodecoys for the SARS-CoV-2 Spike protein to bind to, according to a new pre-clinical study.
news
New approach for treating cystic fibrosis shows success in mice
Researchers have developed a potential strategy to treat cystic fibrosis, using oligonucleotides to correct certain gene defects.
